Macrocyclic compounds as HCV entry inhibitors

Patent metadata

Field	Value
Publication number	US-9624245-B2
Application number	US-201414765910-A
Country	US
Kind code	B2
Filing date	Feb 4, 2014
Priority date	Feb 7, 2013
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

First claim

What is claimed is:

1. A compound of formula I

where:
a, b and c are each nitrogen;
Q is an alkylene or alkenylene chain containing 1 oxetane group and 0-6 groups selected from O, NR 3 , S, S(O), S(O 2 ), C(O)O, C(O)NR 4 , OC(O)NR 4 , NR 4 C(O)NR 4 , and Z, provided that any O or S atom does not directly bond to another O or S atom, such that ring A is 13-32 membered; and wherein the alkylene or alkenylene chain is further substituted with 0-6 alkyl substituents;
R 1 is haloalkyl;
R 2 is selected from the group of cyano, hydrogen, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
R 3 is selected from the group of hydrogen or alkyl;
R 4 is selected from the group of hydrogen or alkyl;
R 5 is selected from the group of hydrogen or alkyl;
X is selected from the group of O, CH 2 , CO, CO 2 , and C(O)NR 5 ; and
Z is selected from the group of C 3-7 cycloalkylene or phenylene;
or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in thereof.

Assignees

• Bristol Myers Squibb Co

Inventors

• Wang Tao
• Zhang Zhongxing
• Yin Zhiwei
• Sun Li-Qiang
• Mull Eric
• Zhao Qian
• Scola Paul Michael

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• C07D498/18

  Bridged systems · CPC title